FDA Okays New Oral CGRP Antagonist for Migraine Prevention FDA Okays New Oral CGRP Antagonist for Migraine Prevention

The US Food and Drug Administration has approved atogepant, a novel calcitonin gene-related peptide receptor antagonist for the prevention of migraine.FDA Approvals
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news

Related Links:

CONCLUSIONS: We presented a rare case of orbital metastasis from ampullary adenocarcinoma. This should be considered in the differential diagnosis of patients with a history of ampullary adenocarcinoma who present with symptoms referring to the relevant locations.PMID:34833456 | DOI:10.3390/medicina57111238
Source: Medicina (Kaunas) - Category: Universities & Medical Training Authors: Source Type: research
Source: Current Pain and Headache Reports - Category: Neurology Source Type: research
ConclusionsBoth anodal and cathodal tDCS are promising for migraine prevention. However, there is a need for larger and rigorous RCTs and standardized procedures. Additionally, the potential benefits and targeted neurostimulation protocols should be assessed for specific subgroups of patients.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research
DiscussionResults of this trial will help to clarify the value of auricular acupressure therapy in preventing and relieving overall and certain adverse events following immunization after injection of COVID-19 vaccine.Trial registrationChina Clinical Trial Registry (ChiCTR) (ChiCTR2100043210). Registered on 8 February, 2021.
Source: Trials - Category: Research Source Type: clinical trials
Doxa Papakonstantinou, Constantinos Tomos International Journal of Workplace Health Management, Vol. ahead-of-print, No. ahead-of-print, pp.- Migraine consists of a chronic neurological disorder with episodic attacks. Migraine prevails in people of their most productive working age, followed by difficulties at work and social functions. This scoping review aims to analyze the economic burden on a workplace due to chronic migraine compared to episodic migraine by focusing on the indirect costs of absenteeism and presenteeism and addressing the research gaps in this field. According to the PRISMA Extens...
Source: International Journal of Workplace Health Management - Category: Occupational Health Authors: Source Type: research
Lancet Infect Dis. 2021 Nov 23:S1473-3099(21)00677-0. doi: 10.1016/S1473-3099(21)00677-0. Online ahead of print.ABSTRACTBACKGROUND: Additional safe and efficacious vaccines are needed to control the COVID-19 pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate.METHODS: HERALD is a randomised, observer-blinded, placebo-controlled, phase 2b/3 clinical trial conducted in 47 centres in ten countries in Europe and Latin America. By use of an interactive web response system and stratification by country and age group (18-60 years and ≥61 years), adults with no history of virolo...
Source: Pain Physician - Category: Anesthesiology Authors: Source Type: research
Updated Date: Fri, 26 Nov 2021 00:00:00 EST
Source: DailyMed Drug Label Updates - Category: Drugs & Pharmacology Source Type: alerts
Updated Date: Fri, 26 Nov 2021 00:00:00 EST
Source: DailyMed Drug Label Updates - Category: Drugs & Pharmacology Source Type: alerts
Updated Date: Fri, 26 Nov 2021 00:00:00 EST
Source: DailyMed Drug Label Updates - Category: Drugs & Pharmacology Source Type: alerts
Updated Date: Fri, 26 Nov 2021 00:00:00 EST
Source: DailyMed Drug Label Updates - Category: Drugs & Pharmacology Source Type: alerts
More News: Brain | Food and Drug Administration (FDA) | Genetics | Headache | Internal Medicine | Migraine | Neurology | Neurosurgery